Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units (Telescope_2)

October 16, 2023 updated by: Hospital Israelita Albert Einstein

Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units: a Stepped-wedge Cluster Randomized Clinical Trial

The objective of this study is to assess whether an intervention package via telemedicine consisting of daily multidisciplinary rounds with a specialist in intensive care medicine, an intervention package provided by a specialized multiprofessional team (nursing, physical therapy and clinical pharmacy) and a management intervention package, focused on quality and safety, reduces the length of stay in ICU patients in Brazil. Our hypothesis is that the intervention package via telemedicine has the potential to decrease the length of stay in ICU patients in Brazil.

The study provides for the implementation of three interventions in association via telemedicine.

  • Daily multidisciplinary rounds conducted by a physician specialized in intensive care medicine
  • Intervention package by specialized multidisciplinary team (nursing, physiotherapy and clinical pharmacy).
  • Management intervention package (quality and safety).

The main questions it aims to answer are:

  • Length of stay in ICU, measured in days, considering the time interval between admission to the ICU and the moment of physical transfer of the patient to another hospital admission area or external transfer.
  • ICU mortality.
  • Mechanical ventilation free time at 28 days.
  • Ventilator-associated events.
  • Patient Mobilization Density.
  • Standard resource use.
  • Standardized mortality rate.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND:

ICU beds represent a scarce and high cost resource. This scenario is aggravated by the scarcity and heterogeneous distribution of specialists in intensive care medicine in Brazil. Telemedicine is an innovative and promising technology, with the possibility of making the daily multidisciplinary round accessible with the presence of intensive care medicine specialists throughout the national territory. In a previous study (Telescope Trial I), it was demonstrated that daily multidisciplinary round conducted via telemedicine by a remotely located medical specialist is a safe and feasible practice. However, little is known about different modalities of telemedicine care in the ICU environment, more specifically, about the impact of interventions performed by a multidisciplinary team (non-medical) and management interventions (quality and safety).

SAMPLE SIZE CALCULATION:

A total sample size of 18,750 to 25,000 patients will be considered to detect a reduction in the length of stay in the ICU on a logarithmic scale of 0.1479 (equivalent to a 1.1-day reduction compared to the baseline), resulting from the intervention package with a significance level of 5% and a minimum power of 95%. This variation in total sample size is due to different estimates of patients per period in the 25 Brazilian ICUs in question. It is estimated that there will be a variation of 30 to 40 patients recruited per month per ICU.

PRIMARY OUTCOME:

Length of stay in the ICU, measured in days, considering the time interval between admission to the ICU and the moment of physical transfer of the patient to another hospital admission area or external transfer.

SECONDARY OUTCOMES:

  • ICU mortality.
  • Mechanical ventilation free time in 28 days.
  • Ventilator-associated events.
  • Patient Mobilization Density.
  • Standard resource use.
  • Standardized mortality rate.

EXPLORATORY OUTCOMES:

  • In-hospital mortality.
  • Adherence to elevated bedside.
  • Adequate prevention of venous thromboembolism.
  • Accidental extubation rate.
  • Rate of patients with adequate glycemic control (defined as blood glucose <70mg/dl to >180mg/dl).
  • Rate of patients - day receiving oral or enteral diet.
  • Rate of patient-day under adequate sedation [defined by Richmond agitation and sedation scale (RASS) = -3 to +].
  • Rate of patients on oxygen therapy in normoxia [defined as peripheral oxygen saturation (SpO2) ≤92% to ≥96%].
  • Rate of ICU readmission within 48 hours.
  • Rate of early reintubation (<48h after extubation).
  • Rate of central venous catheter use.
  • Rate of indwelling urinary catheter use.
  • Central venous catheter use time.
  • Time of indwelling urinary catheter use.

STATISTICAL ANALYSIS:

All analyses will be described in detail in a statistical analysis plan, which will be finalized and submitted for publication before the database is closed and analyses begin. The primary statistical analyses will be conducted according to the intention-to-treat principle. Since ICUs will be randomized (not patients) and outcomes will be measured at the patient level, all analyses will be adjusted for clustering of data.

The primary outcome, length of ICU stay, will be analyzed at the individual level using a generalized linear mixed model, including as fixed effect the group, and considering distributions that can fit an expected right skewness (such as truncated Poisson, Gamma or inverse Gaussian distribution, etc.), choosing the best fit according to model parameters. The goal of the mixed model is to be able to fit random vectors, taking into account the correlation of the observations of individuals in the same cluster. Thus, the model will have as random effect an intercept for each unit. To consider an eventual lack of balance, we will adjust the analysis model for the factors used in the stratification and for the outcome value at the unit level in the pre-randomization period (i.e., mean length of stay in the ICU of each unit), as suggested by the literature. Additionally, we will adjust for factors that have a correlation with length of stay, aiming to decrease variability between units, thus impacting intra cluster correlation and increasing the power of the study. The adjustment factors will be defined after the pre-randomization period data collection, and reported in a statistical analysis plan, published before closing the study database, as specified above. These factors are about severity (SAPS 3) and clinical or surgical profile. In the event of a significant amount of missing data on the primary endpoint, the analysis will be re-evaluated after using multiple imputation with chained equations, assuming that the data will be missing at random. Data collected during the transition period will not be analyzed for primary, secondary or exploratory endpoints.

Sensitivity analyses and subgroups for the primary outcome:

We will define, a priori, the following subgroups for analysis of the primary outcome:

A - ICU length of stay stratified by clinical vs elective surgical and emergency surgical patients.

B - Length of stay in ICU stratified by three groups (lower, middle and upper thirds) of severity determined by SAPS 3 score.

C - ICU length of stay stratified by mechanically ventilated patients on admission (invasive mechanical ventilation).

Similarly, in all other analyses, generalized linear mixed models will be used. Analyses of the pre-specified secondary outcomes and subgroup analyses will not be adjusted for multiple comparisons, thus should be interpreted as exploratory.

Due to the importance of the SAPS 3 severity score, we will evaluate the calibration of the model with data from the pre-randomization period. If necessary, we will recalibrate the model for the study population.

The significance level for all endpoints will be 0.05. All analyses will be performed with R software (version 4.2.0, the version will be updated at the time of the analysis).

REGULATORY STATUS:

The study will be conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Humans Act.

APPROVAL FROM ETHICS AND REGULATORY AUTHORITIES:

The study will be performed according to the national and international guidelines. The Institutional Review Board of the Hospital Israelita Albert Einstein has approved this study (CAAE: 69575123.0.1001.0071). The participating centers will not initiate the study until they have obtained approval from their respective local Institutional Review Boards. The need for informed consent is determined by the Institutional Review Board of each participating center.

Study Type

Interventional

Enrollment (Estimated)

25000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria for Intensive care units:

  • Intensive care units from public or philanthropic hospitals.
  • Intensive care units with physician and nurses available 24 hours a day and physiotherapist available at least ≥ 18 hours a day.

Exclusion Criteria for Intensive care units:

  • Intensive care units with structured multidisciplinary round more than three times a week conducted by an intensive care physician (certified), documented in the medical record, with a fixed duration (>5 min / patient), using some supporting tool (checklist or standard form), goal oriented, based on established protocols, including all the patients admitted to the ICU.
  • Intensive care units already doing audit and feedback with specific planning.
  • Dedicated coronary care units/cardiac intensive care units or other specialized units (cardiac surgery, neurological, burned patients).
  • Step-down units or semi-intensive cardiac care unit.
  • Intensive care units without availability of substitute renal therapy.
  • ICU coordinator specialist in intensive care medicine and management training (MBA in Health Management or equivalent).

Inclusion Criteria for patients:

  • Adult patients (≥ 18 years old).

Exclusion Criteria for patients:

  • Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons).
  • Previously included in the TELESCOPE II trial (for the primary outcome analysis).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sequence 1
Sequence 1 will consist of a 3-month control period, followed by a 3-month transition period, and finally, a 19-month intervention period. The total duration of sequence 1 will be 25 months.
Other: Intervention period

During the intervention period, three interventions will be implemented through telemedicine.

  1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
  2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
  3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Experimental: Sequence 2
Sequence 2 will consist of a 7-month control period, followed by a 3-month transition period, and finally, a 15-month intervention period. The total duration of sequence 2 will be 25 months.
Other: Intervention period

During the intervention period, three interventions will be implemented through telemedicine.

  1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
  2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
  3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Experimental: Sequence 3
Sequence 3 will consist of a 11-month control period, followed by a 3-month transition period, and finally, a 9-month intervention period. The total duration of sequence 3 will be 25 months.
Other: Intervention period

During the intervention period, three interventions will be implemented through telemedicine.

  1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
  2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
  3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Experimental: Sequence 4
Sequence 4 will consist of a 15-month control period, followed by a 3-month transition period, and finally, a 7-month intervention period. The total duration of sequence 4 will be 25 months.
Other: Intervention period

During the intervention period, three interventions will be implemented through telemedicine.

  1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
  2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
  3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Experimental: Sequence 5
Sequence 5 will consist of a 19-month control period, followed by a 3-month transition period, and finally, a 3-month intervention period. The total duration of sequence 5 will be 25 months.
Other: Intervention period

During the intervention period, three interventions will be implemented through telemedicine.

  1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
  2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
  3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intensive Care Unit Length of Stay
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Time until discharge from the intensive care unit
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality in the Intensive Care Unit
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Any death during Intensive Care Unit stay
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Ventilator-free days at day 28
Time Frame: 28 Days
Number od days if the patient was extubated before 28 days and remained alive at day 28. Ventilator-free days at 28 days was the day between extubation and day 28. If the patient dies or remains intubated within 28 days, the patient is awarded zero actual Ventilator-free days at 28 days. The outcome does not indicate if the patient was re-intubated or died within 28 days after being extubated.
28 Days
Ventilator-associated events
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Following the Centers for Disease Control and Prevention (CDC) 2013
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Patient Mobilization Density
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Density of mobilization activities performed.
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Standard resource use
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Calculated based on length of stay in the intensive care unit and adjusted for severity of acute illness
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Standard mortality rate
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Ratio of observed deaths to expected deaths
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
In-hospital mortality
Time Frame: From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days
Any death during hospital stay
From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days
Rate of Patients with Head of the Bed Elevated
Time Frame: 30-45 degrees in patients under mechanical ventilation
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
30-45 degrees in patients under mechanical ventilation
Standard hospital mortality rate
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Ratio of observed hospital deaths to expected hospital deaths
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of adequate prophylaxis for venous thromboembolism
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Adequate prophylaxis for venous thromboembolism
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of adequate glycemic control
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Adequate glycemic control
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Patient-days receiving oral or enteral feeding
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Use of enteral or oral feeding
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Patient-days under light sedation or alert and calm
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Defined as a Richmond Agitation-Sedation Scale (RASS) -3 to +1
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of patients under normoxia
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Defined as oxygen saturation (SpO2) between 92% and 96%
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Intensive care unit readmission
Time Frame: From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days
Readmission less than 48 hours after discharge
From date of randomization until the date of hospital discharge or death, whichever comes first, assessed up to 90 days
Incidence of early reintubation
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Less than 48 hours after extubation
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of central-line catheter use
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Use of central-line catheter use
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of vesical catheter use
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Use of vesical catheter
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Duration of central line catheter use
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Duration in days of central line catheter use
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Duration of vesical catheter use
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Duration in days of vesical catheter use
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of daily multidisciplinary rounds performed
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Daily multidisciplinary rounds performed
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
Rate of recommendations performed, accepted and not validated / daily multidisciplinary rounds.
Time Frame: From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days
recommendations performed during the daily multidisciplinary rounds accepted and not validated
From date of randomization until the date of ICU discharge or death, whichever comes first, assessed up to 90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospital Israelita Albert Einstein

Collaborators

Ministry of Health, Brazil

Investigators

  • Study Director: Adriano J Pereira, MD, PhD., Hospital Israelita Albert Einstein
  • Principal Investigator: Renato CF Chaves, MD, MBA., Hospital Israelita Albert Einstein

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2023

Primary Completion (Estimated)

February 28, 2026

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

June 30, 2023

First Submitted That Met QC Criteria

July 17, 2023

First Posted (Actual)

July 27, 2023

Study Record Updates

Last Update Posted (Actual)

October 17, 2023

Last Update Submitted That Met QC Criteria

October 16, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 5535-23

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data sharing open to researchers not members of the study after two years of the publication of the main study.

IPD Sharing Time Frame

After two years of the first publication

IPD Sharing Access Criteria

Data will be accessed through an online repository protected with password and for secondary analyses according to pre-specified plans.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Telemedicine

Clinical Trials on Intervention period

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe